Loading clinical trials...
Loading clinical trials...
A Phase 1 Multicenter, Open Label Trial Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
Conditions
Interventions
DuoCAR20.19.22-D95
Fludarabine (Conditional therapy)
+1 more
Locations
1
United States
University of Kansas Cancer Center
Westwood, Kansas, United States
Start Date
March 31, 2025
Primary Completion Date
March 1, 2030
Completion Date
March 1, 2040
Last Updated
April 6, 2025
NCT07523555
NCT06395103
NCT05272384
NCT07223021
NCT05674175
NCT06189391
Lead Sponsor
University of Kansas Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions